Compare Cognizant Technology Solutions Corp (CTSH) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Illumina, Inc. — how do they compare? Cognizant Technology Solutions Corp trades at $57.8 (market cap $26.40B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Cognizant Technology Solutions Corp and Illumina, Inc. are close in size by market cap, and Cognizant Technology Solutions Corp pays a 2.25% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| CTSH | ILMN | |
|---|---|---|
Market Cap | $26.40B | $29.12B |
Sector | Technology | Health |
52-Week High | $86.70 | $205.10 |
52-Week Low | $38.73 | $91.00 |
Enterprise Value | $27.44B | $30.48B |
Dividend Yield | 2.25% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
